Trial Profile

A Double-Blind, Placebo-Controlled Assessment of the Tolerability and Efficacy of XT-150 for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Nov 2023 Results of post hoc analyses assessing efficacy presented at the ACR Convergence 2023.
15 Nov 2023 Results assessing safety of XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee presented at the ACR Convergence 2023
20 Mar 2023 According to Xalud Therapeutics Media Release, results of pooled gait data using 2 trials (NCT03282149 and NCT04124042) presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com